Kolexia
Greillier Laurent Pneumologie
Greillier Laurent
Pneumologie
Hôpital Nord Marseille
Marseille, France
694 Activités
386 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Mésothéliome Mésothéliome malin Métastase tumorale Tumeurs de la plèvre Carcinomes Thymome

Collaborateurs

Voir plus
Barlesi Fabrice
Barlesi Fabrice
Gustave-Roussy, Villejuif, France
Tomasini Pascale
Tomasini Pascale
Hôpital Nord Marseille, Marseille, France
Mazieres Julien
Mazieres Julien
Hôpital Rangueil, Toulouse, France
Chouaid Christos
Chouaid Christos
Centre Hospitalier Intercommunal Créteil, Créteil, France

Industries

Voir plus
Sanofi
25 collaboration(s)
Dernière en 2023
AstraZeneca
24 collaboration(s)
Dernière en 2023
MSD
24 collaboration(s)
Dernière en 2023
BMS
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Essai Clinique (National Cancer Institute)   21 mars 2024
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma: An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
Essai Clinique (Roche)   20 mars 2024
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE): Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE)
Essai Clinique (Innate Pharma)   13 mars 2024
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer: A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma
Essai Clinique (Dwight Owen)   12 mars 2024
BOUNCE: A Multicentre, Randomised, Phase II Trial of Brigatinib Consolidation Versus Observation or Durvalumab in Patients With Unresectable Stage III NSCLC and ALK-rearrangement, After Definitive Chemo-radiotherapy
Essai Clinique (Takeda Pharmaceutical)   12 mars 2024
KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma: A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma
Essai Clinique (Jiangsu Alphamab Biopharmaceuticals Co., Ltd)   10 mars 2024
Resected -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Therapeutic advances in medical oncology   06 mars 2024
HER2: A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
Essai Clinique (Enliven Therapeutics)   01 mars 2024
ADEPPT: A Multicentre, Single-arm Phase II Trial of Adagrasib in Patients With KRASG12C-mutant NSCLC, Including the Elderly (≥70 Years) or Patients With Poor Performance Status
Essai Clinique (Mirati Therapeutics Inc.)   22 février 2024
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
NPJ precision oncology   16 février 2024